Access to anti-retroviral drugs, female in Belize

Belize: Access to anti-retroviral drugs, female was 51.0% in 2024. ◆ Volatile

Latest (2024)
51.0%
Change on year
up 4.1%
World rank
118th
of 141 countries
All-time high
51.0%
in 2024
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, female in Belize, 2000–2024

02040602000201220242000: 0 %2001: 0 %2002: 2 %2003: 6 %2004: 5 %2005: 9 %2006: 11 %2007: 14 %2008: 18 %2009: 26 %2010: 28 %2011: 34 %2012: 34 %2013: 36 %2014: 36 %2015: 39 %2016: 41 %2017: 42 %2018: 44 %2019: 45 %2020: 45 %2021: 46 %2022: 48 %2023: 49 %2024: 51 %

Source: UNAIDS estimates. Measured in %.

Analysis

In 2024, access to anti-retroviral drugs, female in Belize stood at 51.0%. That is the highest value across all 25 years on record.

That represents a change of up 4.1% on the previous year and up 41.7% over ten years.

Over the whole period, access to anti-retroviral drugs, female in Belize peaked at 51.0% in 2024 and was at its lowest, 0.0%, in 2000.

That places Belize 118th out of 141 countries with data for 2024, putting it in the bottom quarter.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, female in Belize, year by year

Annual values for Access to anti-retroviral drugs, female (%) in Belize, 2000 to 2024.
Year % Change
2000 0.0%
2001 0.0%
2002 2.0%
2003 6.0% +200.0%
2004 5.0% -16.7%
2005 9.0% +80.0%
2006 11.0% +22.2%
2007 14.0% +27.3%
2008 18.0% +28.6%
2009 26.0% +44.4%
2010 28.0% +7.7%
2011 34.0% +21.4%
2012 34.0% +0.0%
2013 36.0% +5.9%
2014 36.0% +0.0%
2015 39.0% +8.3%
2016 41.0% +5.1%
2017 42.0% +2.4%
2018 44.0% +4.8%
2019 45.0% +2.3%
2020 45.0% +0.0%
2021 46.0% +2.2%
2022 48.0% +4.3%
2023 49.0% +2.1%
2024 51.0% +4.1%

Averages by decade

DecadeAverage LowestHighest Years
2000s 9.1% 0.0% 26.0% 10
2010s 37.9% 28.0% 45.0% 10
2020s 47.8% 45.0% 51.0% 5

Countries ranked near Belize

  1. 116 Armenia 52.0% compare
  2. 116 Libya 52.0% compare
  3. 118 Ghana 51.0% compare
  4. 118 Papua New Guinea 51.0% compare
  5. 118 South Sudan 51.0% compare

See the full ranking of 160 places →

More gender data for Belize

All data for Belize →

Frequently asked questions

What is access to anti-retroviral drugs, female in Belize?
Access to anti-retroviral drugs, female in Belize was 51.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, female recorded in Belize?
The highest recorded value was 51.0% in 2024.
What is the lowest access to anti-retroviral drugs, female recorded in Belize?
The lowest recorded value was 0.0% in 2000.
How does Belize rank for access to anti-retroviral drugs, female?
Belize ranks 118th out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, female rising or falling in Belize?
Over the last ten years it is up 41.7%. The long-run trend across the full record is volatile.
Where does this Belize data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, female (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, female in Belize. Statizoid, drawing on UNAIDS estimates. Retrieved 05 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/belize/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/belize/">Access to anti-retroviral drugs, female in Belize</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, female (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,925 data points, 2000–2024
Last refreshed

The percentage of adult females living with HIV who are receiving antiretroviral therapy.